Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 82572-04-1 | MDL No. : | MFCD07369798 |
Formula : | C12H14ClN | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | ZTNKTVBJMXQOBQ-SBSPUUFOSA-N |
M.W : | 207.70 | Pubchem ID : | 12314893 |
Synonyms : |
|
Num. heavy atoms : | 14 |
Num. arom. heavy atoms : | 10 |
Fraction Csp3 : | 0.17 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 1.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 63.39 |
TPSA : | 26.02 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.03 cm/s |
Log Po/w (iLOGP) : | 0.0 |
Log Po/w (XLOGP3) : | 3.57 |
Log Po/w (WLOGP) : | 3.34 |
Log Po/w (MLOGP) : | 3.12 |
Log Po/w (SILICOS-IT) : | 2.77 |
Consensus Log Po/w : | 2.56 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 1.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.84 |
Solubility : | 0.0301 mg/ml ; 0.000145 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.8 |
Solubility : | 0.0328 mg/ml ; 0.000158 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.14 |
Solubility : | 0.0149 mg/ml ; 0.0000718 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 2.0 |
Synthetic accessibility : | 1.26 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
67% | Stage #1: With sodium cyanoborohydride In methanol at 20℃; for 20 h; Stage #2: With hydrogenchloride In diethyl ether at 0℃; for 13 h; |
General procedure: To a solution of amine hydrochloride (1 mmol) in methanol (10 mL) was added the aldehyde bisulfite adduct (1.12 mmol). To the resulting suspension NaCNBH3 (2.5mmol) was slowly added, and the mixture was stirred for 20 h at rt. Then, the evaporation of the mixture furnished a residue which was partitioned between a 5N NaOH solution and EtOAc. The aqueous phase was extracted with EtOAc and thecombined organic phases were dried and evaporated to give a residue which was dissolved in Et2O and treated with Et2O-HCl (0.6 N). The resulting suspension was cooled for 13 h at 0°C and the precipitated white solid was filtered and dried in vacuo to afford the amine 12-24. |
[ 40280-57-7 ]
1-(Naphthalen-1-yl)ethanamine hydrochloride
Similarity: 1.00
[ 51600-24-9 ]
(S)-1-(Naphthalen-1-yl)ethanamine hydrochloride
Similarity: 1.00
[ 151777-96-7 ]
(R)-1-(Anthracen-9-yl)ethanamine hydrochloride
Similarity: 1.00
[ 1630984-19-8 ]
(S)-1-(Naphthalen-2-yl)ethanamine hydrochloride
Similarity: 0.96
[ 241488-97-1 ]
(R)-1-(Anthracen-9-yl)ethanamine
Similarity: 0.96
[ 40280-57-7 ]
1-(Naphthalen-1-yl)ethanamine hydrochloride
Similarity: 1.00
[ 51600-24-9 ]
(S)-1-(Naphthalen-1-yl)ethanamine hydrochloride
Similarity: 1.00
[ 151777-96-7 ]
(R)-1-(Anthracen-9-yl)ethanamine hydrochloride
Similarity: 1.00
[ 1630984-19-8 ]
(S)-1-(Naphthalen-2-yl)ethanamine hydrochloride
Similarity: 0.96
[ 241488-97-1 ]
(R)-1-(Anthracen-9-yl)ethanamine
Similarity: 0.96